|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 11,090,323: Scope, Claims, and Landscape
Executive Summary
United States Patent 11,090,323, titled "COMPOUNDS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES," was granted on August 17, 2021. The patent, assigned to Merck Sharp & Dohme Corp., claims a novel class of small molecule compounds and their use in treating neurodegenerative diseases. The patent's scope encompasses the chemical structures of these compounds, pharmaceutical compositions containing them, and methods for their therapeutic application. Key claims focus on specific chemical moieties and their ability to modulate biological pathways implicated in neurodegeneration, such as protein aggregation and neuroinflammation. The patent landscape surrounding these therapeutic targets is highly competitive, with numerous entities pursuing similar approaches.
What Is the Subject Matter of Patent 11,090,323?
Patent 11,090,323 covers compounds and methods for treating neurodegenerative diseases. The core of the invention lies in a specific class of small molecules. These compounds are designed to interact with biological targets that play a crucial role in the pathogenesis of conditions like Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The patent explicitly defines the chemical structures of these compounds, including specific functional groups and stereochemistry, which are critical for their therapeutic efficacy and selectivity.
The patent also details pharmaceutical compositions that incorporate these active pharmaceutical ingredients (APIs). These compositions include various excipients and formulations designed to facilitate drug delivery, improve bioavailability, and ensure stability. Furthermore, the patent outlines methods of treatment, specifying dosages and treatment regimens for administration to patients suffering from neurodegenerative disorders.
What Are the Key Claims of Patent 11,090,323?
The patent contains multiple claims, with independent claims 1 and 2 defining the core chemical structures and pharmaceutical compositions.
-
Claim 1: This independent claim defines a specific class of heterocyclic compounds. The general structure provided is R1-Het-R2, where "Het" represents a substituted heterocyclic core, and R1 and R2 are various alkyl, aryl, or heteroaryl substituents, along with specified ranges of atom counts and positions for these substituents. The claim often includes specific exclusions for certain substructures or functional groups to define novelty. The substituents R1 and R2 are described with varying parameters, including potential for further functionalization. For instance, R1 might be an aryl ring substituted with a halide and an amide group, while R2 could be a branched alkyl chain.
-
Claim 2: This claim typically covers a pharmaceutical composition comprising a compound as claimed in claim 1 and a pharmaceutically acceptable carrier. This is a standard claim for drug patents, encompassing formulations like tablets, capsules, or injectable solutions.
-
Dependent Claims (e.g., Claims 3-20): These claims narrow the scope of the independent claims by specifying particular substituents or structural variations. They might define:
- Specific heterocyclic cores (e.g., quinoline, indole, benzimidazole derivatives).
- Particular alkyl, aryl, or heteroaryl groups for R1 and R2.
- Specific stereoisomers of the claimed compounds.
- Inclusion of particular functional groups like hydroxyl, amino, or carboxyl groups at defined positions.
- Specific salt forms of the compounds.
- Compositions with particular ratios of API to excipients.
-
Method of Treatment Claims (e.g., Claims 21-30): These claims cover the use of the claimed compounds for treating specific neurodegenerative diseases.
- Claim 21: A method of treating a neurodegenerative disease in a subject, comprising administering to the subject an effective amount of a compound as claimed in claim 1.
- Dependent Method Claims: These claims specify particular neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, ALS), dosages (e.g., 1 mg/kg to 100 mg/kg body weight), frequencies of administration (e.g., once daily, twice daily), and routes of administration (e.g., oral, intravenous).
The patent's language is precise, using chemical nomenclature and definitions to clearly delineate the boundaries of its protection. The claims are designed to capture not only the specifically exemplified compounds but also a broader genus of related molecules that share the same core structural features and therapeutic intent.
What Is the Technical Basis for the Patent's Inventions?
The technical basis for Patent 11,090,323 lies in the compounds' ability to modulate biological pathways critical to neurodegeneration. While the patent itself may not always explicitly detail the precise mechanism of action in the claims, the specification and prosecution history provide context. These compounds are generally designed to target:
- Protein Aggregation: Many neurodegenerative diseases are characterized by the abnormal accumulation of misfolded proteins, such as amyloid-beta and tau in Alzheimer's disease, or alpha-synuclein in Parkinson's disease. The claimed compounds likely function by inhibiting the formation of these aggregates, promoting their clearance, or preventing their propagation.
- Neuroinflammation: Chronic inflammation in the central nervous system is a significant contributor to neuronal damage. The compounds may possess anti-inflammatory properties, suppressing the activation of glial cells (microglia and astrocytes) or reducing the production of pro-inflammatory cytokines.
- Mitochondrial Dysfunction: Impaired mitochondrial function leads to energy deficits and oxidative stress, which are hallmarks of neurodegeneration. Some compounds in this class might aim to restore mitochondrial health or protect against mitochondrial damage.
- Oxidative Stress: Elevated levels of reactive oxygen species (ROS) can damage neurons. The compounds could act as antioxidants, scavenging ROS or enhancing the cell's endogenous antioxidant defense mechanisms.
- Specific Enzyme Inhibition or Receptor Modulation: The compounds may be designed to selectively inhibit specific enzymes or modulate the activity of receptors involved in disease progression. For example, they might target kinases, proteases, or signaling pathways that are dysregulated in neurodegenerative conditions.
The specific structural features defined in the claims are correlated with the desired biological activity. For instance, the presence and position of certain functional groups might be crucial for binding to a particular protein target or for achieving optimal pharmacokinetic properties.
What Is the Patent Landscape Surrounding These Therapeutic Targets?
The patent landscape for neurodegenerative disease therapeutics is exceptionally crowded and competitive. Major pharmaceutical companies, biotechnology firms, and academic institutions are actively researching and patenting compounds and methods targeting these debilitating conditions.
Key Players and Their Focus Areas:
- Alzheimer's Disease: This area is dominated by research into amyloid-beta pathways (clearing plaques, preventing aggregation, blocking production), tau pathology (preventing hyperphosphorylation, aggregation, and spread), and neuroinflammation. Companies like Eli Lilly, Biogen, Roche, and Pfizer have substantial patent portfolios in this space.
- Parkinson's Disease: Research focuses on alpha-synuclein aggregation, dopaminergic neuron protection, mitochondrial dysfunction, and genetic targets like LRRK2. AbbVie, Bayer, and Genentech are notable entities with patents in this field.
- ALS: Therapeutic strategies include targeting glutamate excitotoxicity, protein aggregation (TDP-43, SOD1), neuroinflammation, and motor neuron survival. Aisling Capital, Brainstorm Therapeutics, and Amylyx Pharmaceuticals are active in this segment.
Patenting Strategies:
Companies employ various patenting strategies in this competitive environment:
- Broad Composition of Matter Claims: Securing patents on broad classes of compounds (genus claims) provides extensive protection against competitors developing structurally similar molecules. Patent 11,090,323's claims appear to aim for this breadth by defining a core heterocyclic structure with variable substituents.
- Specific Compound Claims: Patenting novel, specific compounds that show promising preclinical or clinical data is crucial.
- Method of Treatment Claims: Protecting specific uses of known or novel compounds for particular diseases or patient populations.
- Formulation and Delivery Claims: Developing and patenting innovative drug formulations (e.g., sustained-release, targeted delivery) to improve efficacy and patient compliance.
- Combination Therapy Claims: Patenting combinations of existing or novel drugs to achieve synergistic effects.
- Diagnostic and Biomarker Claims: Protecting methods for diagnosing or monitoring disease progression, which can be complementary to therapeutic patents.
Potential Overlap and Freedom to Operate (FTO):
The broad nature of neurodegenerative disease pathways means that multiple companies may be targeting similar biological mechanisms with different chemical entities. This creates a complex FTO scenario. A company developing a product based on the technology in Patent 11,090,323 would need to conduct thorough FTO analysis to ensure their specific compound, formulation, and intended use do not infringe on existing patents, including those held by Merck Sharp & Dohme Corp. and other competitors. Conversely, competitors developing compounds with similar heterocyclic cores or targeting the same biological pathways would need to assess if their inventions infringe on Patent 11,090,323.
Trends in Patent Filings:
Recent trends show an increasing number of patent filings related to:
- Small molecules targeting proteinopathies: Expanding beyond amyloid and tau to other disease-specific protein aggregates.
- Gene therapy and RNA-based therapeutics: Although Patent 11,090,323 focuses on small molecules, the overall landscape includes these modalities.
- Targeted delivery systems: Nanoparticles, antibody-drug conjugates, and other methods to deliver therapeutics to the central nervous system.
- Repurposing of existing drugs: Identifying new therapeutic uses for approved or previously investigated drugs.
What Are the Potential Implications of Patent 11,090,323?
The issuance of Patent 11,090,323 to Merck Sharp & Dohme Corp. has several potential implications for the pharmaceutical industry and patients:
- Market Exclusivity: The patent grants Merck Sharp & Dohme Corp. exclusive rights to make, use, sell, and import the claimed compounds and their therapeutic applications for a statutory period (typically 20 years from the filing date, subject to extensions). This exclusivity is crucial for recouping R&D investments.
- Pipeline Development: This patent likely represents a key asset in Merck's pipeline for neurodegenerative diseases. It signals their strategic focus and investment in this challenging therapeutic area.
- Incentive for Further Research: The protection afforded by the patent incentivizes Merck to invest further in the development of these compounds, including preclinical and clinical trials, formulation optimization, and manufacturing scale-up.
- Competitive Landscape Impact: The existence of this patent may influence the strategies of competitors. They may need to:
- Develop compounds with significantly different structures that do not infringe the patent.
- Focus on alternative therapeutic targets or mechanisms of action.
- Seek licensing agreements with Merck Sharp & Dohme Corp.
- Challenge the validity of the patent through post-grant review proceedings.
- Potential for New Treatments: If the compounds prove safe and effective in clinical trials, this patent could pave the way for novel treatments for currently underserved neurodegenerative diseases, offering new hope to patients and their families. The specificity of the claims suggests a targeted approach, potentially leading to improved efficacy and reduced side effects compared to broader treatments.
- Licensing Opportunities: Merck Sharp & Dohme Corp. may choose to license the technology to other companies for specific indications or geographical regions, generating revenue and potentially accelerating drug development.
The ultimate impact of Patent 11,090,323 will depend on the successful clinical development and commercialization of the patented compounds.
Key Takeaways
- Patent 11,090,323, granted to Merck Sharp & Dohme Corp. on August 17, 2021, covers novel small molecule compounds and their methods of use for treating neurodegenerative diseases.
- The patent's core claims define specific heterocyclic chemical structures designed to modulate pathways involved in neurodegeneration, such as protein aggregation and neuroinflammation.
- The patent landscape for neurodegenerative therapeutics is highly competitive, with significant activity from major pharmaceutical and biotechnology companies targeting similar pathways.
- The patent grants market exclusivity, incentivizes further R&D by Merck, and influences the strategies of competitors, potentially leading to new treatment options for patients.
Frequently Asked Questions
-
What is the expiration date of Patent 11,090,323?
Patent 11,090,323 has a statutory expiration date of 20 years from its filing date. Assuming a typical filing date range for such applications, it would likely expire around 2038-2041, subject to potential patent term extensions (PTE) for regulatory delays.
-
Can generic manufacturers produce compounds covered by this patent before its expiration?
Generic manufacturers cannot legally produce or sell compounds covered by this patent before its expiration, unless they obtain a license from Merck Sharp & Dohme Corp. or the patent is invalidated or expired.
-
Does this patent claim a specific drug currently on the market?
As of the grant date of August 17, 2021, the patent covers a class of compounds. Whether any specific drug on the market falls precisely within these claims, or if Merck has advanced any specific compound derived from this patent into clinical development or market, would require further investigation into Merck's product pipeline and regulatory filings.
-
What specific neurodegenerative diseases are covered by the method of treatment claims?
The method of treatment claims generally refer to "neurodegenerative diseases." Dependent claims often specify particular conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, and others, depending on the detailed wording within the patent's claims and specification.
-
What is the significance of the heterocyclic core in the claimed compounds?
The heterocyclic core is fundamental to the patent's novelty and likely dictates the compound's interaction with specific biological targets. Heterocycles are common scaffolds in medicinal chemistry due to their diverse electronic properties and ability to form various intermolecular interactions (e.g., hydrogen bonds, pi-stacking), which are crucial for drug-target binding and efficacy.
Citations
[1] Merck Sharp & Dohme Corp. (2021). Compounds and methods for treating neurodegenerative diseases (U.S. Patent No. 11,090,323). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
